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Introduction: The incidence of melanoma has been increasing in the last decades. A
retrospective Hungarian epidemiological study provided real-world data on incidence and
mortality rates. There have been changing trends in incidence in Hungary in the last
decade and mortality decreased, shifting mortality-to-incidence rate ratios (MIR). MIR is an
indicator of cancer management quality.
Objectives: Our aim is to show the changes of melanoma MIR in Hungary between 2011
and 2018 and to compare the real-world evidence-based results of our Hungarian
nationwide retrospective study with other European countries.
Methods: MIR is calculated from the age-specific standardized incidence and mortality
rates from our study. Annual MIR values are presented for the total population and for both
sexes between 2011 and 2018, along with 95% confidence intervals. Comparison with
European countries are shown for 2012 and 2018 based on the GLOBOCAN database
and Eurostat health care expenditure per capita data.
Results: MIR decreased by 0.035 during the study years. The decrease was same in both
sexes (0.031). Male had higher MIRs in all study years. In both 2012 and 2018, HungarianMIR
in both sexes was lower than the European Union average (males: 0.192 vs. 0.212 and 0.148
vs. 0.174 respectively, women: 0.107 vs. 0.129 and 0.083 vs. 0.107 respectively).October 2021 | Volume 11 | Article 7455501
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Frontiers in Oncology | www.frontiersin.orgDiscussion: Hungarian mortality-to-incidence ratio is the lowest in Central and Eastern
Europe and is close to the level of Western and Northern European countries. The results
are driven by the high number of new diagnosed melanoma cases.Keywords: melanoma, mortality-to-incidence ratio, mortality rate, incidence rate, HungaryINTRODUCTION
In recent decades, the incidence of melanoma has been
continuously increasing (1–3). Melanoma was the 5th most
common cancer for females in Europe in both 2012 and 2018
(estimated age-adjusted standardized rates [ASR] per 100,000:
13.1 and 17.7 respectively) and 9th in 2012, 7th in 2018 for males
(estimated ASR: 13.1 and 18.4 respectively) (4, 5). Despite the
growing trends, there are signs that incidence of melanoma is
stabilizing in some regions, e.g. in North America or Scandinavia
(2, 3). The mortality of melanoma showed increasing trends,
similarly to incidence (6, 7), however, there are regions where
mortality is decreasing (8–10), including Europe (ASR per
100,000 in 2012: 3.1 for males, 1.9 for females, in 2018: 2.8 for
males, 1.7 for females) (4, 5). Our recent epidemiological study
presented a change in Hungarian melanoma incidence trend in
the last decade and confirmed a decrease in mortality, as
well (11).
While incidence and mortality are good measures and useful
tools for comparability, the rates themselves may not show the
quality of care, as mortality can increase in parallel with rising
incidence, despite that the ratio is not changing (12). Mortality-
to-incidence ratios (MIR) have been used for more than 40 years,
first as a measure of completeness of cancer registries (13, 14).
Where quality of data is good, MIR can be a valid proxy indicator
for survival estimates (calculated as 1-MIR) (14–16), and has
already been used in multiple cancer types (17–21), including
melanoma (22–24). Despite this, the use of MIR for survival
estimation is mathematically questionable as the calculation does
not use the same population for incidence and mortality (13).
MIR is a good tool for international comparisons, as it is
easily calculable with access to good quality data and using
standardized rates which allows cross-country comparison
(25). Studies on various types of cancer in OECD countries
also discussed the potential of MIR as a measure for evaluation
the success of cancer surveillance and screening (16, 17, 26).
Studies generally found reverse correlation between health-
related expenditure and MIR or development and MIR in
multiple cancer types (18, 20, 23). The GLOBOCAN database
of the International Agency for Research on Cancer (IARC)
contains the best available evidence on age-standardized cancer-
specific incidence and mortality. There have been analyses using
the GLOBOCAN data to compare the MIRs of participating
countries (4, 23, 27). The latest versions of studies about
European countries uses the 2012 and 2018 GLOBOCAN data
(4, 5) which could serve as a base for MIR analysis and evaluation
of changes between 2012 and 2018.
Our aim is to use Hungarian real-world data from our recent
“Real-world retrospective Analysis on the Melanoma Management2
pattern on the basis of countrywide Hungarian registry (RAMM)”
study that is based on the National Health Insurance Fund (NHIF)
database and that of the Central Statistical Office (CSO) from 2011
to 2018 instead of calculating from estimates. Using population level
data allows us to measure the size and change of MIR and position
Hungary accurately among European countries in aspect of MIR.
Previously we found that age-standardized incidence rates were
higher in males and varied between 28.28 and 34.57/100,000
person-years (PYs), and between 22.63 and 26.72/100,000 PYs in
females and mortality rates varied between 4.73 and 5.98/100,000
PYs in males and between 2.33 and 3.20/100,000 PYs in
females (11).MATERIALS AND METHODS
The RAMM study was a nationwide, retrospective, longitudinal
study conducted using the databases of the Hungarian NHIF and
CSO. The NHIF database covers the entirety of the Hungarian
population with social insurance coverage with ICD-10 coding
information about in- and outpatient visits. The CSO database
contains annual cause-specific mortality data of Hungarian citizens.
Our epidemiological study included patients with melanoma
(ICD-10 code: C43) diagnosed between January 1, 2011 and
December 31, 2018 who were at least 20 years old at the time of
diagnosis. A minimum of two occurrences of ICD-10 C34 in
medical records were required for inclusion. Hungarian
population sizes for standardization calculations and data on
cause-specific mortality (date, crude numbers) were obtained
from the CSO. Calculated incidence and mortality rates from
crude numbers were expressed as age-standardized rates (ASRs,
per 100,000 PYs). ASRs are presented using two different
population sets: the European Standard Population from (ESP)
1976 and 2013. Different standardization was necessary to allow
for a direct comparison with recent GLOBOCAN data that uses
the ESP 1976 dataset for European analyses and to evaluate the
change of melanoma MIR in recent years (ESP 2013). More
details on the identification of patients with malignant
melanoma were described in our previous article where we
reported the main epidemiology results of our study (11).
Mortality-to-incidence ratio was calculated by dividing the
age-standardized mortality rate by the age-standardized
incidence rate per 100,000 PYs. Annual MIR values are
presented for the total population and for both sexes between
2011 and 2018. Results from 2012 and 2018 are compared with
European countries using GLOBOCAN data from the same
years. European regional country division is based on the
GLOBOCAN publications. We also investigate the correlation
between health expenditure per capita and MIR for EuropeanOctober 2021 | Volume 11 | Article 745550
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expenditure data. Countries not covered in the Eurostat database
will be excluded from the analysis (28).
Statistical Analysis
Linear regression was applied to estimate the annual change of
MIR: the outcome variable was the MIR, the explanatory variable
was the observed year. Statistical significance level was set at the
probability of 0.05. We used R version 4.0.2 (2020-06-22) for
calculations. The correlation between health expenditure per




Melanoma incidence was increasing until 2015, which was
followed by a gradual decrease until the end of the study
period (ESP 2013), while melanoma mortality started to
decrease in 2014. MIR varied between 0.145 and 0.166 in the
total melanoma population from 2011 to 2014 and remained
constant at around 0.130 since 2015 (Figure 1). The regression
coefficient was -0.005, corresponding to a change of -0.035 for
the whole study period (95% CI: -0.056 to -0.013; p=0.0076).
MIR was lower in women than in men in all study years, with
MIR values ranging from 0.156 to 0.201 in men and from 0.087
to 0.131 in women (Figure 2). Sex-specific MIR trends had
minor differences from the total population. MIR in male
patients had a peak in 2012, which was followed by a larger
drop, and a small and steady increase until 2016. MIR among
female patients was increasing between 2011 and 2014, afterFrontiers in Oncology | www.frontiersin.org 3which it considerably decreased to 0.087 by 2015 and slowly
increased until the end of the study period. The change of MIR
was equal for males (-0.031; 95% CI: -0.059 to -0.003; p=0.0335)
and for females (-0.031; 95% CI: -0.066 to 0.003; p=0.0686).
MIR values based on ESP 1976 standardization showed
similar trends, with MIRs of 0.150 (male 0.194, female 0.107)
in 2012, and 0.113 (male 0.148, female 0.082) in 2018
(Supplementary Table 1).
Hungarian MIR Compared to
European Countries
The age-specific burden of melanoma is similar in European
countries (Supplementary Figure 1) (29), with mortality rates
being more similar to each other than incidence. The average
European MIR in 2012 was 0.245 for males and 0.163 for females
and changed to 0.202 for males and 0.130 for females in 2018.
Western Europe (WE) and Northern Europe (NE) had the
lowest MIRs both in 2012 and 2018. Central and Eastern
Europe (CEE) had the highest MIRs in both years. In 2018,
Hungary had the lowest MIR in the CEE region for both sexes),
which was comparable to the WE and NE average (males 0.162
and 0.133, females 0.095 and 0.076 in 2012 and 2018;
respectively). In 2018, MIR in Hungary ranked 8th among
European countries for males, and 6th for females (Figure 3
and Table 1). With the exception of female patients in Southern
Europe, MIR decreased in all regions between 2012 and 2018.
The change in MIR was comparable to the aggregated European
values, indicating a steady improvement in the quality of
melanoma management on the continent (Table 1).
The results of the Spearman’s rank correlation calculation
show strong negative correlation between health expenditure per
capita and MIR in both 2012 (males R=-0.663, p<0.000, females
R=-0.699, p<0.000) and 2018 (males R=-0.800, p<0.000, females
R=-0.761, p<0.000) regardless of sex (Figure 4). Our results areFIGURE 1 | Age-standardized incidence rates, mortality rates, and mortality-to-incidence ratios of melanoma in Hungary between 2011 and 2018 (per 100,000
person-years, using ESP 2013).October 2021 | Volume 11 | Article 745550
Várnai et al. Improving Hungarian Melanoma Management Indicatorin line with the findings of Forsea et al. (23). Health expenditure
(HE) per capita increased in all countries in the period with the
exception of Greece. There were no HE data on Malta and
Slovenia for 2012, thus those plot points are only visualized for
2018. R2 in 2012 was 0.391 in males, 0.417 in females and in 2018
0.525 in males, 0.470 in females. Hungary and Czechia showed as
notable exceptions in both 2012 and 2018, with noticeably lower
HE per capita from other countries with comparable MIR. The
difference from other countries was more distinguishable in
males than in females.DISCUSSION
Our nationwide study was the first to examine the incidence and
mortality of melanoma as well as the MIR and its changes over a
8-year period in Hungary (23). We found a decrease of 0.035 in
MIR during the whole study period with similar decreases in
both sexes and male patients having higher MIRs in all study
years. Hungarian MIR was lower than the European average both
in 2012 and 2018 in both sexes.
The mortality-to-incidence ratio provides an alternative
means to assess the burden of a disease and quality of care by
presenting mortality after accounting for incidence. MIR can be
interpreted as a quality indicator used for international
comparisons and for the identification of racial and sex
disparities in cancer outcomes (12, 14–16). Low values can be
attributed to the success of screening, quality of care, or access to
modern melanoma therapies. In their analysis, Forsea et al.
calculated MIRs for melanoma across Europe based on 2008
GLOBOCAN data and found the highest ratios in Central and
Eastern Europe (0.35 on average) and the lowest ratios in
Western Europe (0.13 on average). Furthermore, they found a
strong inverse correlation between MIRs and total healthFrontiers in Oncology | www.frontiersin.org 4expenditure per capita in European countries (r=–0.76, p<0.05)
(23). Good quality data is required for internationally
comparable results (25). Our study showed that using real-
world population data can result in a somewhat different
measure than using an estimate (Figure 3), as the incidence
and mortality rates in the RAMM study were lower than the
GLOBOCAN estimates. In the current study, MIRs varied
between 0.156 and 0.201 in men and between 0.087 and 0.131
in women during the 2011–2018 study period, showing a
decreasing trend in both sexes. These values are comparable to
MIRs reported by Forsea et al. for Western European countries,
and far below the data reported for CEE countries. Furthermore,
while the volume and accuracy of melanoma diagnosis in
Hungary resulted in higher absolute incidence rates compared
to other CEE countries, our study shows a decline in annual
incidence rates starting from 2015. Our findings show very
similar cases to the numbers of the National Cancer Registry
(e.g. 2012: Registry 2291 vs 2360, in 2018: Registry 2778 vs 2528)
which gathers epidemiological data in Hungary for over 20 years
(30). The simultaneous decrease in MIR suggests that apart from
incidence, melanoma mortality also started to decrease recently,
which may be attributed to several factors including the relatively
high access to innovative therapies and high health expenditure
per capita compared to neighboring CEE countries as reported
by Kandolf Sekulovic et al. (31) or possibly the success of
secondary prevention in screening and diagnosis.
An important factor shapingHungarian incidence patterns could
be the successful local implementation of the Euromelanoma
educational and prevention campaign, which has been active for
more than two decades across Europe. Hungary joined the
Euromelanoma campaign relatively early in 2007, which led to the
subsequent increase in the number of screening and awareness
campaigns. The first Euromelanoma campaign in Hungary was
organized in 2009 (see Supplementary Table 2) (32), and theFIGURE 2 | Age-standardized incidence rates, mortality rates, and mortality-to-incidence ratios of melanoma per sex in Hungary between 2011 and 2018 (per
100,000 person-years, using ESP 2013).October 2021 | Volume 11 | Article 745550
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timely diagnosis of clinically suspected melanoma ever since (33).
The Hungarian Dermatological Society performed over 30,000
birthmark screenings free of charge with the involvement of more
than100 volunteeringdermatologists since 2007 (34). Earlydetection
has an important effect on pathological prognostic factors including
melanoma (Breslow) thickness and Clark level, both of which are
strongly associated with survival (35). The Hungarian NationalFrontiers in Oncology | www.frontiersin.org 5Institute of Oncology analyzed cutaneous malignant melanoma
cases and found a significant decrease in mean Breslow thickness
from 2.2 mm to 1.6 mm (p<0.001) and a non-significant decrease in
Clark level between 1998 and 2008 (36). Accordingly, the earlier
detection of the disease led to an increase in incidence and a decrease
inmortality, as shown by our previous study (11). The improvement
in melanoma management was also reflected by the increase in the
meanageof the totalprevalentmelanomapopulation, suggesting thatFIGURE 3 | Mortality-to-incidence ratios of melanoma by sex in Europe in 2012 and 2018 using the ESP 1976 dataset, all countries with data (numbers indicate the
difference between 2018 and 2012 values). Note: Hungary (GLOBOCAN) refers to the publication of Ferlay et al. (4); Hungary RAMM refers to our findings. Our
findings are highlighted with different coloration for distinction: males are green (2012 light, 2018 dark), women are yellow (2012 light, 2018 dark).TABLE 1 | Mortality-to-incidence ratios of melanoma by sex in European regions in 2012 and 2018 using the European Standard Population 1976 dataset (4, 5).
Region Male Female
2012 2018 Difference 2012 2018 Difference
Hungary (RAMM) 0.194 0.148 0.046 0.107 0.082 0.025
Europe 0.246 0.203 0.043 0.164 0.130 0.033
EU-27 (2012)/EU-28 (2018) 0.212 0.174 0.038 0.130 0.107 n. a.
Western Europe 0.188 0.133 0.056 0.114 0.076 0.038
Northern Europe 0.194 0.162 0.031 0.113 0.095 0.019
Central and Eastern Europe 0.443 0.395 0.048 0.317 0.282 0.035
Southern Europe 0.228 0.216 0.012 0.140 0.143 -0.003October 2021 | Volume 11 | Artn.a., not appicable.icle 745550
Várnai et al. Improving Hungarian Melanoma Management Indicatorpatients die of other causes, which results in an increasing gap
between all-cause and cause-specific mortality. Disability-adjusted
life-year (DALY) analyses have found that the burden of melanoma
affects male patients and elder patients the greatest. The studies call
formore prevention efforts to diagnosemelanoma at earlier stages, as
life-years spent with disability is lower than life-years lost. Earlier
diagnoses could lead to reduced melanoma burden, with life-years
lost turning into life-years with disability (37–39). The studies were
publishedbefore the onset of novel immunotherapeutic agents,when
researches were ongoing in both drug therapies and predictive
markers that may also affect melanoma DALY (39).
Apart from early detection, the availability of modern
pharmaceutical therapies has also had a significant effect on
melanoma survival, especially in the metastatic stage. TargetedFrontiers in Oncology | www.frontiersin.org 6therapies (BRAF and MEK-inhibitors) and immune checkpoint
inhibitors (ipilimumab, nivolumab, pembrolizumab) have provided
significant survival benefits for patients with stage III–IV melanoma
(40). Access to modern treatments is an indicator of the
performance of healthcare systems (31). The IMS-IQVIA
database shows that targeted therapies and immune checkpoint
inhibitors were introduced into Hungarian clinical practice shortly
after their introduction in Western European countries, which is
reflected by similar MIR values in these populations (41).
Furthermore, the increasing complexity of advanced cancer care
brought about several new challenges and revealed disparities in
everyday clinical practice. Therefore, in line with international
initiatives (42), the European Cancer Organization essential
requirements for quality cancer care expert group recommendedA
B
FIGURE 4 | Correlation between melanoma mortality-to-incidence ratios and health expenditure per capita in 2012 and 2018 using the ESP 1976 dataset. (A) male
patients, (B) female patients. Diamond shaped plot points indicate Hungary, triangle shaped plot points indicate Czechia.October 2021 | Volume 11 | Article 745550
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collaboration with, specialized melanoma centers where both a core
multidisciplinary team and an extended team of allied professionals
were available, and which were subject to quality and audit
procedures (43). In the interest of high-quality comprehensive
cancer control, Hungarian healthcare organizations implemented
the recommendations for high-quality patient care in melanoma
management according to progressivity level (44) and nominated 7
clinics as “Melanoma Centres” to promote clinical experience with
modern immune and targeted therapies (45). Improved melanoma
management as shown by our results reflects the validity and
success of centre-based melanoma care (11). Furthermore, almost
the entirety of the Hungarian population is covered by social
insurance with full access to reimbursed therapies. Individuals in
risk groups can get screening without age limitations.
Our study found higher MIR values among male patients during
the whole study period, which is in line with observations from
other countries. Gender-specific differences in mortality have been
reported for the majority of tumour types (46). Data from the
American Academy of Dermatological National Skin Cancer
Screening Program showed that although men aged 50 years or
older constituted only a quarter of melanoma screenings, theyFrontiers in Oncology | www.frontiersin.org 7accounted for almost half of confirmed diagnoses (47).
Furthermore, Rat et al. reported significantly lower adherence to
targeted skin cancer screening programs compared to women (48),
and the majority of attendants at Euromelanoma screening
campaigns were also found to be female in 2009–2010 (73% in
Hungary) (33). Skin cancer risk awareness, the involvement of
primary healthcare physicians and dermatologists, and
comprehensive information and education provided by the media
are important elements in melanoma diagnosis.
Hungary and the Czech Republic were the only two CEE
countries with comparable MIR to WE and NE countries in both
sexes (Figure 3). Figure 5 shows that these two countries had the
highest incidence rates in the CEE region, which may be attributed
to successful screening campaigns. Access to innovative melanoma
medicines (targeted therapies and/or immunotherapies) is ≥90% in
both countries (percentages show patients treated with said drugs),
thus diagnosed patients have access to the best available therapies
that shows in mortality rates (31, 49). While there are studies, which
found that total health expenditure or expenditure on oncology
drugs correlates with MIR, none is concerning melanoma-specific
treatments (23, 50). Our results using Eurostat HE data also showed
that although higher total HE per capita correlated with better MIRFIGURE 5 | Age-standardized melanoma incidence and mortality rates by sex in Europe, 2018 (ESP 1976 dataset).October 2021 | Volume 11 | Article 745550
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and the Czech Republic was substantially better than it would have
been expected based on their HE per capita (Figure 4). As the age-
specific incidence rates in 2012 showed, was comparable to several
other European countries, e.g. to Germany and the UK
(Supplementary Figure 1). This suggests successful screening
practices, possibly due to the Euromelanoma campaigns (33).
However, apart from these exceptions, evidence suggests that
higher volume of expenditure on melanoma drugs leads to
better outcomes.
MIR as a tool has its limitations. Despite previous proposals, the
MIR should not be used in survival estimations as the population
included in incidence and mortality are not necessarily the same, as
advised by Ellis and colleagues (13). We would rather recommend
using MIR as a rapid tool for trend evaluations and international
comparisons for melanoma management, due to the availability of
epidemiological data.
In conclusion, the Hungarian mortality-to-incidence ratio of
melanoma was the lowest in Central and Eastern Europe and
comparable to that of Western and Northern European countries.
The results are potentially due the outstanding number of new
diagnosed melanoma cases as a success of melanoma screening
campaigns in Hungary. Our results show that efforts for early
detection of melanoma can improve mortality-to-incidence rates.
Further analyses could explore the effect of the access to health
care resources in the therapeutic area.DATA AVAILABILITY STATEMENT
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26. Sunkara V, Hébert JR. The Colorectal Cancer Mortality-to-Incidence Ratio as
an Indicator of Global Cancer Screening and Care. Cancer (2015) 121
(10):1563–9. doi: 10.1002/cncr.29228
27. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al.
Cancer Incidence and Mortality Worldwide: Sources, Methods and Major
Patterns in GLOBOCAN 2012. Int J Cancer (2015) 136(5):E359–86. doi:
10.1002/ijc.29210
28. Health Care Expenditure by Function (Hlth_Sha11_Hc) (2021). Available at:
https://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=hlth_sha11_hc.
29. European Cancer Information System. Historical Incidence and Mortality
Data (Melanoma, 2012). European Commission (2021).
30. Cancer Registry Statistics. (2021). Available at: https://onkol.hu/nemzeti-
rakregiszter/.
31. Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, et al.
Access to Innovative Medicines for Metastatic Melanoma Worldwide: Melanoma
World Society and European Association of Dermato-Oncology Survey in 34
Countries. Eur J Cancer (2018) 104:201–9. doi: 10.1016/j.ejca.2018.09.013
32. Stratigos AJ, Forsea AM, van der Leest RJT, de Vries E, Nagore E, Bulliard J-L, et al.
Euromelanoma: A Dermatology-Led European Campaign Against Nonmelanoma
Skin Cancer and Cutaneous Melanoma. Past, Present and Future. Br J Dermatol
(2012) 167(s2):99–104. doi: 10.1111/j.1365-2133.2012.11092.x
33. van der Leest RJ, de Vries E, Bulliard JL, Paoli J, Peris K, Stratigos AJ, et al. The
Euromelanoma Skin Cancer Prevention Campaign in Europe: Characteristics
and Results of 2009 and 2010. J Eur Acad Dermatol Venereol (2011) 25
(12):1455–65. doi: 10.1111/j.1468-3083.2011.04228.x
34. Hungarian Dermatological Society. Euromelanoma Kampány - Melanoma
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